Edition:
United Kingdom

Genomic Health Inc (GHDX.OQ)

GHDX.OQ on NASDAQ Stock Exchange Global Select Market

65.26USD
23 Oct 2018
Change (% chg)

$-0.58 (-0.88%)
Prev Close
$65.84
Open
$64.61
Day's High
$65.81
Day's Low
$63.10
Volume
24,335
Avg. Vol
115,060
52-wk High
$72.27
52-wk Low
$26.54

Latest Key Developments (Source: Significant Developments)

Genomic Health Reports Q2 Earnings Per Share Of $0.23
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Genomic Health Inc ::GENOMIC HEALTH ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND REPORTS RECENT BUSINESS PROGRESS.Q2 EARNINGS PER SHARE $0.23.Q2 REVENUE $95.6 MILLION VERSUS I/B/E/S VIEW $92.3 MILLION.Q2 EARNINGS PER SHARE VIEW $0.07 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 REVENUE GROWTH BETWEEN 10% TO 15%.SEES FY 2018 REVENUE BETWEEN $366 MILLION - $382 MILLION .SEES FY 2018 GAAP BASIC EPS BETWEEN $0.00 TO $0.14.SEES FY 2018 NON-GAAP BASIC EPS BETWEEN $0.39 TO $0.56.  Full Article

Genomic Health Q2 Earnings Per Share $0.23
Thursday, 2 Aug 2018 

Genomic Health Inc ::GENOMIC HEALTH ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND REPORTS RECENT BUSINESS PROGRESS.Q2 EARNINGS PER SHARE $0.23.Q2 REVENUE $95.6 MILLION VERSUS I/B/E/S VIEW $92.3 MILLION.Q2 EARNINGS PER SHARE VIEW $0.07 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 REVENUE BETWEEN $366- $382.SEES FY 2018 REVENUE GROWTH BETWEEN 10% TO 15%.SEES FY 2018 GAAP BASIC EPS BETWEEN $0.00 TO $0.14.SEES FY 2018 NON-GAAP BASIC EPS BETWEEN $0.39 TO $0.56.  Full Article

Genomic Health Announces Research Collaboration with Janssen Pharma
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Genomic Health Inc ::GENOMIC HEALTH ANNOUNCES RESEARCH COLLABORATION WITH JANSSEN PHARMACEUTICALS TO EVALUATE THE ONCOTYPE DX® GENOMIC PROSTATE SCORE™ TEST FOR POTENTIAL DRUG DEVELOPMENT.GENOMIC HEALTH - AS PER AGREEMENT, CO WILL TEST SAMPLES FROM JANSSEN STUDIES TO EXAMINE ASSOCIATION OF GENOMIC PROSTATE SCORE RESULTS WITH CLINICAL OUTCOMES.  Full Article

Genomic Health And Cleveland Diagnostics Announce Strategic Collaboration To Develop And Commercialize New Prostate Cancer Tests
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Genomic Health Inc ::GENOMIC HEALTH AND CLEVELAND DIAGNOSTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE NEW PROSTATE CANCER TESTS.GENOMIC HEALTH-DEAL TO PROVIDE CO WITH EXCLUSIVE GLOBAL RIGHTS TO DEVELOP CANCER TESTS BASED ON CLEVELAND DIAGNOSTICS' ISOPSA REAGENT & SIA TECHNOLOGY​.GENOMIC HEALTH INC - ‍GENOMIC HEALTH IS EXPECTED TO BEGIN ADDITIONAL DEVELOPMENT AND CLINICAL VALIDATION OF FIRST HIGH-PSA REFLEX TEST IN 2018​.GENOMIC HEALTH INC - ‍GENOMIC HEALTH WILL MAKE A CONVERTIBLE NOTE INVESTMENT IN CLEVELAND DIAGNOSTICS IN PRINCIPAL AMOUNT OF $2 MILLION IN Q4 OF 2017​.  Full Article

Genomic Health Q3 loss per share $0.06
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Genomic Health Inc ::Genomic Health announces third quarter 2017 financial results and reports recent business progress.Q3 loss per share $0.06.Q3 revenue $83.8 million versus I/B/E/S view $86.9 million.Q3 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S.Genomic Health - ‍expects to meet low end of FY revenue guidance, which is $345 million, excluding estimated hurricane impact on revenue of about $3 million in Q3​.Genomic Health Inc - ‍expects to deliver full-year profit, excluding $3.2 million cost of biocartis transaction​.  Full Article

Genomic Health Q4 EPS $0.04
Tuesday, 14 Feb 2017 

Genomic Health Inc : Genomic health announces 2016 fourth quarter and year-end financial results, provides 2017 financial outlook . Q4 earnings per share $0.04 . Q4 revenue $82.7 million versus i/b/e/s view $84.1 million . Sees fy 2017 revenue up 11 percent . Q4 earnings per share view $-0.01 -- Thomson Reuters I/B/E/S . Genomic health inc- for full year ending december 31, 2017 sees total product revenue of between $355 to $370 million . Fy2017 revenue view $363.3 million -- Thomson Reuters I/B/E/S .Genomic health - in 2017 at mid-point of revenue guidance, we expect to deliver 11 percent revenue growth and positive net income for full year.  Full Article

Photo

Many women with early-stage breast cancer can skip chemotherapy: study

CHICAGO Some 70 percent of women with early-stage breast cancer and an intermediate risk of cancer recurrence can safely skip chemotherapy after their tumors have been removed, U.S. researchers said on Sunday. | Video